Christophe Weber (Miho Takahashi/The Yomiuri Shimbun via AP Images)
December 22, 2021 10:19 AM EST
FDA+

Months af­ter miss­ing its PDU­FA date, FDA slaps down Takeda's old Shire drug for eosinophilic esophagi­tis

Nicole DeFeudis

Editor

Take­da CEO Christophe We­ber thought he had a win in the bag for TAK-721 — one of the ex­per­i­men­tal drugs spot­light­ed in the com­pa­ny’s

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Ex­clu­sive: Col­or Health alums raise $10M for new start­up, us­ing AI for reg­u­la­to­ry work

A service from the Financial Times